|Mr. Scott Raymond Ward M.S., MS, B.Sc.||Chairman, Pres & CEO||1.13M||N/A||1960|
|Mr. Jeffrey S. Points||Chief Financial Officer||363.86k||N/A||1977|
|Ms. Rhonda J. Robb||Chief Operating Officer||900k||N/A||1968|
|Mr. Alexander Rosenstein||Gen. Counsel & Corp. Sec.||374.21k||N/A||1972|
|Mr. John E. Nielsen||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Cardiovascular Systems, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 3. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 6; Compensation: 1.